Aug 26, 2009 | Laboratory Management and Operations, Laboratory News, Laboratory Pathology
Deal with Abbott Labs gives Neogenomics access to proprietary probes Diagnostic testing for melanoma generates a substantial number of tests annually, making it a lucrative target for any clinical laboratory or biotech company that can develop an assay that utilizes state-of-the-art molecular technologies and offers improved detection and accuracy. Once company working to develop such a new diagnostic test for melanoma is Neogenomics, Inc. (OTC:NGNM.OB). It announced an agreement with Abbott...
